RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit
Regenerative Medical Technologies Group (OTC:RMTG) announced the soft opening of its subsidiary Cellgenic's advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The COFEPRIS-licensed facility will manufacture cell-based therapies including mesenchymal stem cells, exosomes, and NK cells.
The facility, set for full-scale operations by January 2026, will serve as both a Stem Cell Collection Center and Stem Cell Bank. The company reported Q1 2025 sales of $1.35M, showing 67% growth with operational profits of $134,000. The opening coincides with the 2025 ISSCA Regenerative Medicine Global Summit, expecting to attract over 200 physicians and scientists from 30+ countries.
Regenerative Medical Technologies Group (OTC:RMTG) ha annunciato l'apertura iniziale della sua controllata Cellgenic e del suo avanzato stabilimento per la produzione di terapie cellulari a Cancun, Messico, prevista per settembre 2025. L'impianto, autorizzato da COFEPRIS, produrrà terapie a base di cellule come cellule staminali mesenchimali, esosomi e cellule NK.
Lo stabilimento, che sarà operativo a pieno regime entro gennaio 2026, funzionerà sia come Centro di Raccolta di Cellule Staminali sia come Banca delle Cellule Staminali. La società ha riportato vendite nel Q1 2025 pari a $1,35M, con una crescita del 67% e utili operativi di $134.000. L'inaugurazione coincide con il Summit Globale 2025 di ISSCA sulla Medicina Rigenerativa, che si prevede attirerà oltre 200 medici e scienziati provenienti da più di 30 paesi.
Regenerative Medical Technologies Group (OTC:RMTG) anunció la apertura inicial de su subsidiaria Cellgenic y su moderna planta de fabricación de terapias celulares en Cancún, México, durante septiembre de 2025. La instalación, con licencia de COFEPRIS, producirá terapias basadas en células, incluidas células madre mesenquimales, exosomas y células NK.
La planta, prevista para operaciones a plena escala en enero de 2026, funcionará tanto como Centro de Recolección de Células Madre como Banco de Células Madre. La compañía informó ventas del 1T 2025 por $1,35M, con un crecimiento del 67% y utilidades operativas de $134,000. La apertura coincide con la Cumbre Global de Medicina Regenerativa ISSCA 2025, que se espera atraiga a más de 200 médicos y científicos de más de 30 países.
Regenerative Medical Technologies Group (OTC:RMTG)는 자회사 셀젠릭(Cellgenic)의 첨단 세포치료제 제조시설을 2025년 9월 멕시코 칸쿤에서 시범 운영한다고 발표했습니다. COFEPRIS 허가를 받은 시설은 중간엽 줄기세포, 엑소좀, NK세포 등 세포 기반 치료제를 생산할 예정입니다.
이 시설은 2026년 1월 정식 가동을 목표로 하며, 줄기세포 채취센터이자 줄기세포 은행 역할을 하게 됩니다. 회사는 2025년 1분기 매출 $1.35M을 보고했으며, 이는 67% 증가한 수치로 영업이익은 $134,000입니다. 개소식은 2025년 ISSCA 재생의학 글로벌 서밋과 겹치며, 30개국 이상에서 200명 이상의 의사와 과학자가 참석할 것으로 예상됩니다.
Regenerative Medical Technologies Group (OTC:RMTG) a annoncé l'ouverture en douceur de sa filiale Cellgenic et de son installation avancée de fabrication de thérapies cellulaires à Cancún, Mexique, en septembre 2025. L'installation, autorisée par la COFEPRIS, produira des thérapies à base de cellules, notamment des cellules souches mésenchymateuses, des exosomes et des cellules NK.
Prévoyée pour entrer en pleine production en janvier 2026, l'usine servira à la fois de centre de collecte de cellules souches et de banque de cellules souches. La société a déclaré des ventes au 1er trimestre 2025 de $1,35M, soit une croissance de 67% et des bénéfices opérationnels de $134 000. L'ouverture coïncide avec le Sommet mondial ISSCA sur la médecine régénérative 2025, qui devrait attirer plus de 200 médecins et scientifiques de plus de 30 pays.
Regenerative Medical Technologies Group (OTC:RMTG) gab die Soft-Opening seiner Tochtergesellschaft Cellgenic und deren hochentwickelter Zelltherapie-Produktionsstätte in Cancún, Mexiko, im September 2025 bekannt. Die von COFEPRIS lizenzierte Anlage wird zellbasierte Therapien herstellen, darunter mesenchymale Stammzellen, Exosomen und NK-Zellen.
Die Anlage, die bis Januar 2026 den Vollbetrieb aufnehmen soll, wird sowohl als Stammzell-Sammelzentrum als auch als Stammzellbank dienen. Das Unternehmen meldete Umsätze im 1. Quartal 2025 von $1,35M, was einem Wachstum von 67% entspricht, und operative Gewinne von $134.000. Die Eröffnung fällt mit dem ISSCA Regenerative Medicine Global Summit 2025 zusammen, zu dem voraussichtlich über 200 Ärzte und Wissenschaftler aus mehr als 30 Ländern erwartet werden.
- Q1 2025 revenue showed strong 67% growth to $1.35M with $134,000 in operational profits
- COFEPRIS authorization obtained for both Stem Cell Collection Center and Stem Cell Bank operations
- Strategic expansion into manufacturing operations with ISO-classified cleanrooms and GMP-aligned workflows
- Facility will serve an existing affiliate network spanning 30+ countries
- Recent clinic relocation caused a temporary dip in procedures revenue
- Full-scale operations won't begin until January 2026
RMTG Subsidiary Cellgenic to Host Soft Opening of Advanced Cell Therapy Manufacturing Lab in Cancun During September ISSCA Global Summit
COFEPRIS-Licensed Facility Positions Company for Full-Scale Operations by January 2026
LAS VEGAS, NV / ACCESS Newswire / August 25, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced that its subsidiary Cellgenic will host the soft opening of its advanced cell therapy manufacturing facility in Cancun, Mexico during September 2025. The opening will coincide with the 2025 ISSCA Regenerative Medicine Global Summit, organized by the International Society for Stem Cell Application (ISSCA), RMTG's educational and scientific division through its Global Stem Cells Group subsidiary.
Strategic Manufacturing Infrastructure:
The soft opening represents a significant milestone in RMTG's international expansion strategy, with plans to establish specialized infrastructure designed for the controlled manufacture, preservation, and distribution of human cellular products. The strategically located Cancun facility will support production of investigational and regulated cell-based therapies, including mesenchymal stem cells (MSCs), exosomes, natural killer (NK) cells, and other biologics for orthopedics, neurology, pain management, aesthetic medicine, and longevity-focused therapies.
Regulatory Compliance and Market Positioning:
• COFEPRIS Authorization: Laboratory fully licensed by Mexico's federal health authority to operate as both a Stem Cell Collection Center and Stem Cell Bank
• International Standards: ISO-classified cleanrooms, cryopreservation systems, GMP-aligned workflows, and digital batch traceability systems
• Revenue Generation: Full-scale operations expected by January 2026, adding manufacturing revenue streams to RMTG's existing affiliate network spanning 30+ countries
• Training Integration: Designated areas for physician education programs through ISSCA platform, creating additional certification and training revenue opportunities
• Global Distribution: Facility positioned to serve physicians, clinics, and scientific partners both locally and internationally within regulatory framework
"This laboratory represents a pivotal step in our expansion strategy," said David Christensen, CEO of RMTG. "We believe it provides a foundation for scientific growth, and we are optimistic about its potential to support regulated, high-quality cell-based technologies for physicians and institutions worldwide."
Market Opportunity and Summit Integration:
The soft opening is expected to attract more than 200 physicians, scientists, and biotech leaders from over 30 countries attending the ISSCA Global Summit. The facility tour will provide attendees with an opportunity to observe manufacturing systems and quality safeguards, demonstrating RMTG's commitment to compliance and scientific rigor in the rapidly expanding regenerative medicine market.
"Our intention with this laboratory is to strengthen the infrastructure needed for responsible and scalable regenerative medicine," said Benito Novas, Founder of Global Stem Cells Group. "With the COFEPRIS authorizations in place, we believe this facility will serve as a strategic base to support the production and distribution of therapies that meet rigorous safety and quality expectations."
Operational Timeline and Revenue Impact:
Six months ago, we made the bold move to significantly expand our manufacturing operations. To do that we took the existing clinic and lab and separated the clinic to a new location, leaving that entire real estate footprint available for the necessary space required to increase our lab / manufacturing operation. That relocation of the clinic did cause a dip in procedures revenue, but we anticipate revenues to be strong again by the end of Q3.
The Cancun facility operates under Mexico's legal and biosafety framework for cellular product collection, processing, storage, and release. Full manufacturing operations beginning January 2026 will complement RMTG's existing revenue model, which generated Q1 2025 sales of
The laboratory will serve as a center for ongoing research, clinical collaboration, and physician education through ISSCA training programs. These programs support healthcare professionals in developing expertise with cell-based protocols while maintaining emphasis on ethics, compliance, and patient safety.
About RMTG:
RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. The Company's integrated approach combines clinical operations, product distribution, manufacturing capabilities, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, manufacturing operations timeline, facility performance, or regulatory compliance. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that the Cellgenic facility will achieve full operational status by January 2026, that manufacturing operations will generate anticipated revenues, or that regulatory authorizations will remain in effect. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
Contact: David Christensen, CEO and President Regenerative Medical Technologies Group, Inc. investor.relations@regenmedtechgroup.com | (800) 956-3935
SOURCE: Regenerative Medical Technology Group
View the original press release on ACCESS Newswire
FAQ
When will RMTG's Cellgenic facility in Cancun begin full operations?
What was RMTG's revenue in Q1 2025?
What types of cell therapies will RMTG's Cancun facility manufacture?
What regulatory approvals does RMTG's Cancun facility have?
How many countries does RMTG's affiliate network cover?
